Navigation Links
Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
Date:10/9/2008

SKOKIE, Ill., Oct. 9 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, announced today that Robert J. De Vaere has joined the Company as executive vice president and chief financial officer.

"Bob is an experienced executive who brings more than 28 years of financial management experience to Horizon, including the last decade in healthcare with both public and private companies," said Timothy P. Walbert, president and chief executive officer. "During his career, Bob has been instrumental in numerous M&A transactions as well as an IPO and will be an important part of Horizon's future growth."

Mr. De Vaere's most recent position was as senior vice president, finance and administration and chief financial officer of IDM Pharma, Inc. (Nasdaq: IDMI), a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. Additionally, Mr. De Vaere served as vice president, finance and administration and chief financial officer of IDM Pharma from August 2005 to March 2006, and was vice president and chief financial officer of Epimmune from May 2000 until the business combination with IDM Pharma in August 2005.

Mr. De Vaere has also served as chief financial officer of Nexa Orthopedics, which was acquired by Tornier, Inc. and vice president of finance and administration and chief financial office of Vista Medical Technologies, Inc., a medical device company.

Earlier in his career, Mr. De Vaere held accounting, finance and administrative positions within the electronics and aerospace industries. Mr. De Vaere received a bachelor's degree from the University of California, Los Angeles.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Out beyond the horizon
2. Out beyond the horizon
3. BioHorizons Announces Agreement to Purchase Implant Logic Systems
4. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
5. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
6. BioHorizons Announces the Purchase of Implant Logic Systems
7. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
8. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
9. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
10. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017   Parent Project Muscular Dystrophy (PPMD) , ... Duchenne muscular dystrophy (Duchenne) , today announced a $600,000 ... of Technology (NJIT) and Talem Technologies (Talem) as part ... to assist people living with Duchenne. PPMD is ... an embedded computer, software, a force sensor and a ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports Medicine ... Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long Island ... anterior cervical discectomy and fusion on a 42 year old female who was ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in December ... Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the award of ... of Defense has announced the award of a new Advanced Regenerative Manufacturing Institute ...
(Date:1/18/2017)... ... 18, 2017 , ... Researchers from a new study are stating that if levels ... prostate cancer treatment, this indicates there is still remaining prostate cancer cells that are more ... PSA test has always been an indicator of whether a man’s prostate cancer is ...
Breaking Biology Technology:
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, ... global financial services provider, today announced an agreement with NuData ... biometrics, to join forces. The partnership will enable clients to ... in compliance with local data protection regulation. ... In order to provide ...
(Date:12/15/2016)... ... has announced the addition of the "Global Military Biometrics Market 2016-2020" ... global military biometrics market to grow at a CAGR of 7.5% during ... on an in-depth market analysis with inputs from industry experts. The report ... The report also includes a discussion of the key vendors operating in ...
(Date:12/15/2016)... HILLS, Mich. , Dec. 15, 2016  There ... unlocking car doors or starting the engine. Continental will ... in Las Vegas . Through the ... (Passive Start and Entry) and biometric elements, the international ... field of vehicle personalization and authentication. "The ...
Breaking Biology News(10 mins):